Medical equipment is one of four businesses remaining at a trimmed-downVarian Associates. The Palo Alto, CA, high-technology firm soldthe last of five non-core businesses last month, as it completedthe initial phase of a restructuring program. A U.K.
Medical equipment is one of four businesses remaining at a trimmed-downVarian Associates. The Palo Alto, CA, high-technology firm soldthe last of five non-core businesses last month, as it completedthe initial phase of a restructuring program. A U.K. broadcasttransmitter company was the last of the five to go.
Varian has raised over $60 million through the sale of nonstrategicbusinesses. These funds will be used in the second phase of thefirm's attempted financial turnaround: improving performance ofits core businesses of electron devices, analytical instruments,semiconductor equipment and medical equipment.
Varian produces linear accelerators for cancer therapy as wellas a variety of components for medical imaging equipment. Thecompany also holds basic patents in medical areas such as magneticresonance spectroscopy (SCAN 2/27/91), although Varian does notmarket MR scanners.
Varian/Eimac of Salt Lake City is a major supplier of replacementx-ray tubes and other imaging components for OEMs and independentservice organizations. Varian Canada Microwave Products is a supplierof power sources to OEMs for use in x-ray generators. The Canadianunit initiated a high-frequency retrofit program for CGR Senographemammography systems last year (SCAN 2/27/91).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.